CN Patent

CN110650963A — (S)-2-((2-((S)-4-(二氟甲基)-2-氧代噁唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]氧氮杂*-9-基)氨基)丙酰胺的多晶型物和固体形式及其制备方法

Assigned to F Hoffmann La Roche AG · Expires 2020-01-03 · 6y expired

What this patent protects

本发明涉及具有以下式I结构的(5)‑2‑((2‑((5)‑4‑(二氟甲基)‑2‑氧代噁唑烷‑3‑基)‑5,6‑二氢苯并[f]咪唑并[1,2‑J][1,4]氧氮杂 ‑9‑基)氨基)丙酰胺(GDC‑0077)(或其立体异构体、几何异构体、互变异构体及药用盐)的结晶多晶型物形式，及制备所述多晶型物形式的方法，

USPTO Abstract

本发明涉及具有以下式I结构的(5)‑2‑((2‑((5)‑4‑(二氟甲基)‑2‑氧代噁唑烷‑3‑基)‑5,6‑二氢苯并[f]咪唑并[1,2‑J][1,4]氧氮杂 ‑9‑基)氨基)丙酰胺(GDC‑0077)(或其立体异构体、几何异构体、互变异构体及药用盐)的结晶多晶型物形式，及制备所述多晶型物形式的方法，

Drugs covered by this patent

Patent Metadata

Patent number
CN110650963A
Jurisdiction
CN
Classification
—
Expires
2020-01-03
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.